Artritis reumatoide temprana

This article reviews some key issues of early rheumatoid arthritis such as the difficulties to recognize this condition during the first months after onset. Therefore, three reference diagnostic criteria have been proposed for any patient presenting with more than three simultaneously inflammed joints, involvement of  metacarpophalangeal or proximal interphalangeal joints and morning stiffness lasting more than 30 minutes. Antibodies to cyclic citrullinated peptides are new markers that can be used for diagnosis. The immediate treatment during the "opportunity window" at the onset of inflammation may avoid the erosive joint damage. The use of synthetic or biological disease modifying medications, specially tumor necrosis factor alpha antagonists, also contribute to this purpose. Primary care physicians should be aware of the early signs of the disease to provide an adequate treatment and referral to specialists.

Saved in:
Bibliographic Details
Main Author: Massardo,Loreto
Format: Digital revista
Language:Spanish / Castilian
Published: Sociedad Médica de Santiago 2008
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008001100015
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-98872008001100015
record_format ojs
spelling oai:scielo:S0034-988720080011000152009-03-23Artritis reumatoide tempranaMassardo,Loreto Arthritis, rheumatold Early diagnosis Tumor necrosis factor-alpha This article reviews some key issues of early rheumatoid arthritis such as the difficulties to recognize this condition during the first months after onset. Therefore, three reference diagnostic criteria have been proposed for any patient presenting with more than three simultaneously inflammed joints, involvement of  metacarpophalangeal or proximal interphalangeal joints and morning stiffness lasting more than 30 minutes. Antibodies to cyclic citrullinated peptides are new markers that can be used for diagnosis. The immediate treatment during the "opportunity window" at the onset of inflammation may avoid the erosive joint damage. The use of synthetic or biological disease modifying medications, specially tumor necrosis factor alpha antagonists, also contribute to this purpose. Primary care physicians should be aware of the early signs of the disease to provide an adequate treatment and referral to specialists.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.136 n.11 20082008-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008001100015es10.4067/S0034-98872008001100015
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language Spanish / Castilian
format Digital
author Massardo,Loreto
spellingShingle Massardo,Loreto
Artritis reumatoide temprana
author_facet Massardo,Loreto
author_sort Massardo,Loreto
title Artritis reumatoide temprana
title_short Artritis reumatoide temprana
title_full Artritis reumatoide temprana
title_fullStr Artritis reumatoide temprana
title_full_unstemmed Artritis reumatoide temprana
title_sort artritis reumatoide temprana
description This article reviews some key issues of early rheumatoid arthritis such as the difficulties to recognize this condition during the first months after onset. Therefore, three reference diagnostic criteria have been proposed for any patient presenting with more than three simultaneously inflammed joints, involvement of  metacarpophalangeal or proximal interphalangeal joints and morning stiffness lasting more than 30 minutes. Antibodies to cyclic citrullinated peptides are new markers that can be used for diagnosis. The immediate treatment during the "opportunity window" at the onset of inflammation may avoid the erosive joint damage. The use of synthetic or biological disease modifying medications, specially tumor necrosis factor alpha antagonists, also contribute to this purpose. Primary care physicians should be aware of the early signs of the disease to provide an adequate treatment and referral to specialists.
publisher Sociedad Médica de Santiago
publishDate 2008
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008001100015
work_keys_str_mv AT massardoloreto artritisreumatoidetemprana
_version_ 1755988272745545728